| Abstrakt: |
A recent study conducted at the Mayo Clinic in Rochester, Minnesota examined the safety of thrombolysis, a treatment for acute ischemic stroke (AIS), in patients with hematologic malignancies. The study found that intravenous thrombolysis was safe for this patient population, with a low incidence of hemorrhagic transformation and post-stroke mortality. Most patients were functionally independent at 90 days post-stroke, including those with active hematologic malignancy. The study suggests that intravenous alteplase should be considered for the management of AIS in patients with hematologic malignancy. This research has been peer-reviewed and provides valuable insights into stroke treatment in this specific patient population. [Extracted from the article] |
